Audentes Therapeutics Garners $65,000,000 Series C Funding

  • Feed Type
  • Date
    10/14/2015
  • Company Name
    Audentes Therapeutics
  • Mailing Address
    101 Montgomery Street. San Francisco, CA 94104 USA
  • Company Description
    Audentes is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated virus (AAV) gene therapy technology.
  • Website
    http://www.audentestx.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $65,000,000
  • Transaction Round
    Series C
  • Proceeds Purposes
    The proceeds from the Series C financing will be primarily used to advance the company’s three lead development programs to key clinical milestones and to establish internal GMP manufacturing capabilities.
  • M&A Terms
  • Venture Investor
    Sofinnova Ventures
  • Venture Investor
    Redmile Group
  • Venture Investor
    RA Capital
  • Venture Investor
    T. Rowe Price
  • Venture Investor
    Rock Springs Capital
  • Venture Investor
    Cormorant Asset Management
  • Venture Investor
    Cowen Capital Partners
  • Venture Investor
    Foresite Capital
  • Venture Investor
    OrbiMed
  • Venture Investor
    5AM Ventures
  • Venture Investor
    Versant Ventures
  • Venture Investor
    Deerfield Capital
  • Venture Investor
    Venrock